Cáncer de tiroides

Referencias

Artículos principales

Haugen BR, Alexander EK, Bible KC, et al; American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.Texto completo  Resumen

Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016 May;22(5):622-39.Texto completo  Resumen

Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610.Texto completo  Resumen

Artículos de referencia

1. Gimm O. Thyroid cancer. Cancer Lett. 2001 Feb 26;163(2):143-56. Resumen

2. Haugen BR, Alexander EK, Bible KC, et al; American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.Texto completo  Resumen

3. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer.1998 Dec 15;83(12):2638-48.Texto completo  Resumen

4. Bertagna F, Treglia G, Piccardo A, et al. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012 Nov;97(11):3866-75. Resumen

5. Phillips JS, Pledger DR, Hilger AW. Rapid thyrotoxicosis in anaplastic thyroid carcinoma. J Laryngol Otol. 2007 Jul;121(7):695-7. Resumen

6. James BC, Mitchell JM, Jeon HD, et al. An update in international trends in incidence rates of thyroid cancer, 1973-2007. Cancer Causes Control. 2018 May;29(4-5):465-473.Texto completo  Resumen

7. National Cancer Institute. Cancer stat facts: thyroid cancer. Surveillance, Epidemiology, and End Results (SEER) Program. [internet publication]Texto completo

8. James BC, Mitchell JM, Jeon HD, et al. An update in international trends in incidence rates of thyroid cancer, 1973-2007. Cancer Causes Control. 2018 May;29(4-5):465-473.Texto completo  Resumen

9. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):332-336.Texto completo  Resumen

10. Grinspoon S, Seely E, eds. 3 perspectives on thyroid cancer: what's new in treatment and research. Endocr News. 2005;30:10-15.

11. Kim TH, Park YJ, Lim JA. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012 Apr 1;118(7):1764-73.Texto completo  Resumen

12. Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016 May;22(5):622-39.Texto completo  Resumen

13. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol. 2003 Aug;12(2):69-90. Resumen

14. Patel KN, Singh B. Genetic considerations in thyroid cancer. Cancer Control. 2006 Apr;13(2):111-8. Resumen

15. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):775-82. Resumen

16. Sherman SI. Thyroid carcinoma. Lancet. 2003 Feb 8;361(9356):501-11. Resumen

17. Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am. 2009 Oct;89(5):1193-204.Texto completo  Resumen

18. Spallek L, Krille L, Reiners C, et al. Adverse effects of iodine thyroid blocking: a systematic review. Radiat Protn Dosimetry. 2012 Jul;150(3):267-77. Resumen

19. American College of Radiology. ACR-AIUM-SPR-SRU practice parameter for the performance and interpretation of diagnostic ultrasound of the extracranial head and neck. 2018 [internet publication].Texto completo

20. Novoa E, Gürtler N, Arnoux A, et al. Role of ultrasound-guided core-needle biopsy in the assessment of head and neck lesions: a meta-analysis and systematic review of the literature. Head Neck. 2012 Oct;34(10):1497-503. Resumen

21. Webb RC, Howard RS, Stojadinovic A, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012 Aug;97(8):2754-63. Resumen

22. Sebag F, Vaillant-Lombard J, Berbis J, et al. Shear wave elastography: a new ultrasound imaging mode for the differential diagnosis of benign and malignant thyroid nodules. J Clin Endocrinol Metab. 2010 Dec;95(12):5281-8. Resumen

23. Rago T, Scutari M, Santini F, et al. Real-time elastosonography: useful tool for refining the presurgical diagnosis in thyroid nodules with indeterminate or nondiagnostic cytology. J Clin Endocrinol Metab. 2010 Dec;95(12):5274-80. Resumen

24. Wu LM, Gu HY, Qu XH, et al. The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: a meta-analysis. Eur J Radiol. 2012 Aug;81(8):1798-805. Resumen

25. Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol. 2019 Jul;72(7):460-7.Texto completo  Resumen

26. Mekel M, Nucera C, Hodin RA, et al. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg. 2010 Jul;200(1):136-43. Resumen

27. Hegedus L. Can elastography stretch our understanding of thyroid histomorphology? J Clin Endocrinol Metab. 2010 Dec;95(12):5213-5. Resumen

28. Hershman JM, Cheng S, Gianoukakis, et al. Update in thyroidology. 2010. J Clin Endocrinol Metab. 2011 Jan;96(1):9-14. Resumen

29. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77.Texto completo  Resumen

30. Balasubramanian SP, Harrison BJ. Systematic review and meta-analysis of sentinel node biopsy in thyroid cancer. Br J Surg. 2011 Mar;98(3):334-44. Resumen

31. Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011;2011:542358.Texto completo  Resumen

32. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov;22(11):1104-39.Texto completo  Resumen

33. Shaha AR. Advances in the management of thyroid cancer. Int J Surg. 2005;3(3):213-20. Resumen

34. Lang BH, Lo CY, Chan WF, et al. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007 Mar;245(3):366-78. Resumen

35. Lang BH, Lo CY, Chan WF, et al. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. Endocr Relat Cancer. 2007 Mar;14(1):29-42. Resumen

36. US Preventive Services Task Force. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA. 2017 May 9;317(18):1882-1887.Texto completo  Resumen

37. Perros P, Boelaert K, Colley S, et al; British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122.Texto completo  Resumen

38. Cobin RH, Gharib H, Bergman DA, et al; Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract. 2001 May-Jun;7(3):202-20.Texto completo  Resumen

39. White ML, Gauger PG, Doherty GM, et al. Central lymph node dissection in differentiated thyroid cancer. World J Surg. 2007 May;31(5):895-904. Resumen

40. Shan CX, Zhang W, Jiang DZ, et al. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope. 2012 Apr;122(4):797-804. Resumen

41. Zetoune T, Keutgen X, Buitrago D, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol. 2010 Dec;17(12):3287-93. Resumen

42. Hughes DT, Doherty GM. Central neck dissection for papillary thyroid cancer. Cancer Control. 2011 Apr;18(2):83-8. Resumen

43. Samraj K, Gurusamy KS. Wound drains following thyroid surgery. Cochrane Database Syst Rev. 2007;(4):CD006099. Resumen

44. Inabnet WB. Surgical management of thyroid cancer. Endocr Pract. 2000 Nov-Dec;6(6):465-8. Resumen

45. Fallahi B, Beiki D, Takavar A, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun. 2012 Mar;33(3):275-82. Resumen

46. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. New Engl J Med. 2012 May 3;366(18):1674-85.Texto completo  Resumen

47. Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011 Dec;150(6):1250-7. Resumen

48. Brose MS, Nutting CM, Jarzab B, et al; DECISION Investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26;384(9940):319-28.Texto completo  Resumen

49. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30.Texto completo  Resumen

50. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41.Texto completo  Resumen

51. Frampton JE. Vandetanib: in medullary thyroid cancer. Drugs. 2012 Jul 9;72(10):1423-36. Resumen

52. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610.Texto completo  Resumen

53. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov;22(11):1104-39.Texto completo  Resumen

54. Salerno P, De Falco V, Tamburrino A, et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010 Jan;95(1):450-5. Resumen

55. Ball DW. Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab. 2010 Jan;95(1):60-1. Resumen

56. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46.Texto completo  Resumen

57. Tappenden P, Carroll C, Hamilton J, et al. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Health Technol Assess. 2019 Feb;23(8):1-144.Texto completo  Resumen

58. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13.Texto completo  Resumen

59. US Food and Drug Administration. FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor. Nov 2018 [internet publication].Texto completo

60. Bhangoo MS, Sigal D. TRK Inhibitors: Clinical Development of Larotrectinib. Curr Oncol Rep. 2019 Feb 4;21(2):14.Texto completo  Resumen

61. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 Feb 22;378(8):731-9.Texto completo  Resumen

62. Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018 May;19(5):705-14.Texto completo  Resumen

63. Fan LJ, Jiang J. Present and future of robot-assisted endoscopic thyroid surgery. Chin Med J (Engl). 2012 Mar;125(5):926-31. Resumen

64. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Dec 1;30(12):1856-1883.Texto completo  Resumen

65. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol. 2002 Jul;3(7):407-14. Resumen

66. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.Texto completo

67. Widder S, Pasieka JL. Primary thyroid lymphomas. Curr Treat Options Oncol. 2004 Aug;5(4):307-13. Resumen

68. Corrigan KL, Williamson H, Elliott Range D, et al. Treatment Outcomes in Anaplastic Thyroid Cancer. J Thyroid Res. 2019;2019:8218949.Texto completo  Resumen

69. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med. 2001;345:512-516. Resumen

70. Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. J Clin Oncol. 2018 Jun 20;36(18):1831-9.Texto completo  Resumen

71. Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011 Oct 1;117(19):4439-46.Texto completo  Resumen

72. Genton CY, Dutoit M, Portmann L, et al. Pathologic fracture of the femur neck as first manifestation of a minute columnar cell carcinoma of the thyroid gland. Pathol Res Pract. 1998;194(12):861-3 Resumen

73. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 Mar;91(3):878-84. Resumen

74. Yoo J, Cosby R, Driedger A. Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review. Curr Oncol. 1991 Jan;11(1):401-11. Resumen

75. Ma C, Xie J, Liu W, Wang G, et al. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database Syst Rev. 2010;(11):CD008302. Resumen

76. Royal College of Physicians (UK). Evidence-based indications for the use of PET-CT in the UK 2016. May 2016. [internet publication].Texto completo

77. American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011 Apr;21(4):335-46.Texto completo  Resumen

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad